A common nerve protein elevated in aggressive neuroblastomas
2015-04-20
(Press-News.org) PHILADELPHIA - A protein produced by nerve cells appears to be elevated in the blood of those with an aggressive form of neuroblastoma. The finding, presented today at the American Association for Cancer Research 2015 Annual Meeting in Philadelphia, could potentially lead to a prognostic test for the disease or be used to monitor its progress.
Neuroblastoma is a pediatric cancer with varying types, ranging from spontaneously regressing to untreatable fatal tumors. Consequently, treatment strategies vary significantly between patients, encompassing different approaches including observation alone or intensive chemo- and radiotherapy.
"Given the severe late effects of anti-cancer treatment administered to infants and children, proper disease stratification is of utmost importance for neuroblastoma patients," explain Joanna Kitlinska, PhD, assistant professor in the department of biochemistry and molecular & cellular biology at Georgetown University Medical Center.
Because of their neuronal origin, neuroblastomas synthesize and release neuropeptide Y (NPY), a small protein normally secreted from mature nerves. In previous research, Kitlinska and her colleagues have shown that NPY, acting via its Y2 and Y5 receptors (Y2R and Y5R), is crucial for maintaining neuroblastoma growth and protecting the tumors from chemotherapy.
"To confirm the clinical relevance of our earlier work and assess NPY and its receptors as potential prognostic factors, we performed clinical study on tissue samples and serum from 87 neuroblastoma patients," Kitlinska explains.
"We have found that NPY is released from aggressive neuroblastoma tumors into the blood, which results in its elevated serum concentrations. These high systemic levels of NPY are associated with several adverse prognostic factors for neuroblastoma and worse survival of neuroblastoma patients. "
She adds that high NPY release is a strong marker of metastatic disease, while the Y5R is present preferentially in invasive neuroblastoma cells. Also, patients with elevated NPY at diagnosis were more likely to have a disease relapse in the future.
"These results support a crucial role for NPY in neuroblastoma biology, particularly in its dissemination and resistance to therapy, and validate the NPY system as a potential therapeutic target and potential prognostic marker for neuroblastoma," she says.
"In contrast to complex genetic analyses currently utilized to assess risk of the disease, the measurement of NPY levels in blood can be converted to a readily available analytical test. Using such easily accessible clinical material will allow for minimally invasive longitudinal monitoring of the disease progression," Kitlinska explains.
"If confirmed by further prospective studies, this finding may have a significant impact on the clinical management of patients with neuroblastoma," she concludes.
INFORMATION:
In addition to Kitlinska, authors include Susana Galli, Jason Tilan, Chao Yang, Jessica Tsuei and Emily Trinh of Georgetown, and Arlene Naranjo and Collin Van Ryn from the University of Florida Children's Oncology Group.
Kitlinska and her co-authors report having no personal financial interests related to the study.
The study was supported by grants from the National Institutes of Health (R01 CA 123211-01, U10CA098543, U10 CA98413-08, 1U10CA180886, and 1U10CA180899).
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.
ELSE PRESS RELEASES FROM THIS DATE:
2015-04-20
A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.
The findings were presented at the American Association of Cancer Research's annual meeting in Philadelphia.
"Increasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer," said Catherine Marinac, UC San Diego doctoral candidate ...
2015-04-20
Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.
Results of the early-phase clinical trial of the therapy, called MPDL3280A, which aims to restore the immune system's ability to recognize and attack cancer cells, are expected to be presented at the American Association for Cancer Research's 2015 Annual Meeting in Philadelphia from April 18-22. Triple-negative breast cancer cells lack expression ...
2015-04-20
TORONTO, April 20, 2015--Although ultrasound remains the primary imaging modality used in prenatal imaging, fetal MRI is playing an increasing role in further evaluation of fetuses suspected of congenital anomalies. As 3-T MRI scanners become more common due to their improved image signal-to-noise ratio and anatomical detail, the benefits of 3-T MRI must be weighed against potential risks to the fetus that may result from the higher field strength.
"MRI is playing an increasingly important role in the assessment of complex prenatal disease," said Kathleen E. Carey, MD, ...
2015-04-20
TORONTO, April 20, 2015--The design of inferior vena cava (IVC) filters for pulmonary embolism prophylaxis, once used almost exclusively for permanent implantation, has progressed to retrievable designs. However, complications can create scenarios in which the routine filter retrieval is either extremely difficult or impossible.
The use of advanced retrieval techniques, such as loop-snare, "sandwich," stiff wire or balloon realignment, forceps retrieval and excimer laser sheath can raise the overall success rate above 98%.
"Implementation of IVC filters is increasing ...
2015-04-20
TORONTO, April 20, 2015--Research comparing the accuracy of three MDCT slice thicknesses has found that 3-mm slices underestimated coronary artery calcium (CAC) scores at every level of calcification. The inaccuracies were caused by partial volume averaging errors.
"Our analysis proved this concept and showed that CAC can be more accurately measured with 0.5 or 1 mm using isotropic data acquisition obtained by a volume scanner at identical radiation dose ," said Farhood Saremi, MD, University of Southern California. "Coronary artery calcium can be more accurately measured ...
2015-04-20
TORONTO, April 20, 2015--Research conducted at the State University of New York Upstate Medical University has found that multiparametric MRI and subsequent fusion of MR images with ultrasound enables a targeted biopsy of high-suspicion foci with increased diagnostic accuracy of prostate cancer over established methods.
For patients on active surveillance for low-risk cancer, multiparametric MRI can better characterize the prostate gland and find occult foci of higher grade disease.
"The need to differentiate a clinically significant cancer from indolent cancers is ...
2015-04-20
TORONTO, April 20, 2015-- Computational fluid dynamics (CFD) simulation based on 3D luminal reconstructions of the coronary artery tree can be used to analyze local flow fields and flow profiling resulting from changes in coronary artery geometry. Research conducted at Curtin University in Perth, Australia, used the technique to identify risk factors for development and progression of coronary artery disease.
Both idealized and realistic coronary models were successfully generated using CFD simulations of hemodynamic flow. Results showed a direct correlation between left ...
2015-04-20
TORONTO, April 20, 2015-- Dual-energy CT (DECT) has several potential applications in the detection, characterization, staging, and follow-up of pancreatic cancer patients, according to a new study conducted at Johns Hopkins University.
"DECT imaging is a promising technique, and it has the potential to improve lesion detection and characterization beyond levels available with single-energy CT imaging," said Satomi Kawamoto, MD, associate professor of radiology and radiological science at Hopkins.
Several studies have shown that DE CT can help assessment of pancreatic ...
2015-04-20
TORONTO, April 20, 2015--A protocol developed by radiologists at the Santa Clara Valley Medical Center reduced CT misadministration at the Santa Clara Valley Medical Center from 18 instances in 60,999 studies to zero in 36,608 in just 10 months. Misadministration includes, but is not limited to, imaging the wrong patient or body part without a physician's order or repeated imaging of a patient without a physician's order.
The best practices protocol includes several levels of assessment, including reverification checklists, workflow clarification, and individual accountability.
"CT ...
2015-04-20
(Bethesda, MD, April 20, 2015) Researchers at the NFCR Center for Cancer System Informatics at MD Anderson Cancer Center have discovered a key factor that may explain drug resistance in glioblastoma (GBM), the most common and deadliest form of brain cancer.
GBM accounts for 17% of all brain tumors, and over 10,000 new cases of GBM are diagnosed in the US each year. Unfortunately - since there are no effective, long-term therapies available - survival is typically less than 17 months.
Approximately 50% of GBMs are known to have mutations in a gene called EGFR. However, ...
LAST 30 PRESS RELEASES:
[Press-News.org] A common nerve protein elevated in aggressive neuroblastomas
